New Jersey 2022-2023 Regular Session

New Jersey Senate Bill S791

Introduced
1/18/22  
Refer
1/18/22  
Report Pass
6/9/22  

Caption

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

Impact

The implementation of S791 will significantly impact state health insurance policies, as it amends existing regulations to include mandatory coverage for prostate cancer screenings. Insurers will be required to provide this coverage without deductibles, copayments, or other cost-sharing mechanisms. This change is expected to not only enhance access to prostate cancer screenings but also encourage more men within the specified age range to undergo testing, potentially leading to earlier diagnoses and better health outcomes.

Summary

Senate Bill S791 aims to expand the requirements for health insurance carriers in New Jersey concerning coverage for prostate cancer screenings. It mandates that all health insurance policies, including those issued or renewed on or after the effective date of this act, provide benefits for annual prostate cancer screening without any cost-sharing for men aged 40 to 75. This legislation is designed to improve early detection and treatment of prostate cancer by ensuring that financial barriers do not prevent access to necessary screenings.

Sentiment

The sentiment surrounding S791 appears to be largely positive, particularly among health advocacy groups and healthcare providers who recognize the importance of accessible preventative care. They argue that eliminating financial barriers is crucial for increasing participation in screening programs. However, some concerns have been raised regarding the potential implications for insurance premiums, with opponents suggesting that increased coverage requirements could lead to higher costs for consumers in the long term.

Contention

Among the notable points of contention in discussions of S791, there is debate over the responsibilities placed on insurance providers and the financial implications of mandated coverages. Stakeholders are divided on whether such legislation may lead to unintended consequences, such as increased premiums or reduced coverage options for consumers. Furthermore, discussions on how to balance necessary healthcare access with the financial realities faced by health insurance providers have been significant throughout the legislative process.

Companion Bills

NJ A2795

Same As Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

Similar Bills

NJ A2795

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

NJ A1841

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

NJ S3060

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

IL HB5103

INS CD-CANCER SCREENINGS

AL SB58

DNA; prohibit taking and disclosure without express consent

IN HB1061

Coverage for cancer screening.

MD SB965

Cancer Screening - Health Insurance and Assessment of Outreach, Education, and Health Disparities

MD HB815

Cancer Screening - Health Insurance and Assessment of Outreach, Education, and Health Disparities